, Tracking Stock Market Picks
Enter Symbol:
BioLineRx, Ltd. (BLRX) [hlAlert]

down 33.65 %

BioLineRx, Ltd. (BLRX) rated Buy with price target $4 by B. Riley & Co.

Posted on: Friday,  Apr 25, 2014  12:00 AM ET by B. Riley & Co

B. Riley & Co rated Buy BioLineRx, Ltd. (NASDAQ: BLRX) on 04/25/2014, when the stock price was $2.05.
Since then, BioLineRx, Ltd. has lost 33.66% as of 09/24/2015's recent price of $1.36.
If you would have followed this B. Riley & Co's recommendation on BLRX, you would have lost 33.65% of your investment in 517 days.

BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients; and BL-5010, a novel formulation under Phase I/II clinical trial for non surgical removal of skin lesions. The company?s product pipeline under pre-clinical stage of development includes BL-1021 for neuropathic pain; BL-2030 for autoimmune diseases; BL-4010 for cancer tumors; BL-4040 for acute kidney failure; BL-5030 for thromboembolic diseases; BL-5040 for inflammatory diseases and pathological weight loss; BL-6010 for type II diabetes; BL-6020 for cancer cachexia; and BL-6030 for bacterial biofilm. It also operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. The company was founded in 2003 and is based in Jerusalem, Israel.

B. Riley's distinguished equity and high yield research is the mainstay of the firm, contributing unparalleled value to our institutional and private clients. Our success is based on our history of uncovering value before anyone else.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/25/2014 12:00 AM Buy
2.05 4.00
as of 10/17/2014
1 Week down  -2.14 %
1 Month down  -15.95 %
3 Months down  -32.17 %
1 YTD down  -33.17 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy